Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 30.11M P/E - EPS this Y 51.40% Ern Qtrly Grth -
Income -38.66M Forward P/E -1.89 EPS next Y 10.40% 50D Avg Chg -86.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -88.00%
Dividend N/A Price/Book 0.76 EPS next 5Y - 52W High Chg -95.00%
Recommedations 2.50 Quick Ratio 0.46 Shares Outstanding 10.77M 52W Low Chg -
Insider Own 26.08% ROA -96.80% Shares Float 8.43M Beta -
Inst Own 6.09% ROE -353.02% Shares Shorted/Prior 30.03K/43.04K Price 1.00
Gross Margin - Profit Margin - Avg. Volume 9,514 Target Price 10.00
Oper. Margin - Earnings Date Nov 7 Volume 224,803 Change 0.00%
About Angion Biomedica Corp.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.

Angion Biomedica Corp. News
11/13/24 Elicio Therapeutics: Q3 Earnings Snapshot
11/13/24 Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
11/07/24 Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
10/31/24 Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
10/24/24 All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
10/16/24 Elicio Therapeutics Reports Inducement Grants
09/13/24 Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
08/28/24 Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/13/24 Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
08/12/24 Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
06/28/24 Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
06/27/24 Elicio Therapeutics Announces Proposed Public Offering
06/27/24 Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
05/23/24 Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
05/16/24 BayWa r.e. and Elicio to build 270MW floating wind farm in France
05/15/24 Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
04/25/24 Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
04/13/24 Robert Connelly Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) CEO is the most bullish insider, and their stock value gained 11%last week
04/05/24 Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
03/29/24 Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
ELTX Chatroom

User Image Woooehoo Posted - 5 days ago

$ELTX so is this gonna run?

User Image Simpson216 Posted - 1 week ago

$ELAB $ELTX

User Image justiceforb_85 Posted - 1 week ago

$ELTX science for their mKRAS-diven vaccine is sound. Looking forward to updated data in December/January. https://elicio.com/press_releases/elicio-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-updates/

User Image justiceforb_85 Posted - 1 week ago

$ELTX promising data. https://elicio.com/press_releases/elicio-therapeutics-presents-updated-translational-data-from-eli-002-phase-1-amplify-7p-study-at-the-society-for-immunotherapy-of-cancer-sitc-2024-annual-meeting/

User Image rajbc Posted - 2 weeks ago

$ELTX what would a fail look like? Clearly any adverse events would prevent progress but this seems unlikely, so the 100+ patients will be expanded for P3 trial soon, but with similar or improved efficacy and safety data from the 25 P1 patients I think the word “breakthrough” will be heavily used, P2 enrollment done by EOY, new data from P1 coming soon…trial for prevention with a BP??

User Image justiceforb_85 Posted - 10/25/24

$ELTX look forward to updated data on ELI-002.

User Image justiceforb_85 Posted - 09/30/24

$GRTS management did not state whether reduction of death risk was statistically significant (CI crosses 1 so I doubt it). Management's interpretation of data this year has been murky. $ELTX has promising data for their vaccine in colon/pancreatic cancer and would be worth a look.

User Image rajbc Posted - 2 months ago

$ELTX exciting times for cancer vaccine efforts, years of failures have set the stage for this albumin mediated delivery of onco peptides to lymph nodes, made possible by insights at MIT and perhaps heralding a new public health frontier. Fingers crossed!

User Image Scooter0732 Posted - 2 months ago

$ELTX should be good got that PK energy in it

User Image justiceforb_85 Posted - 2 months ago

$ELTX remaining hopeful on a successful read-out for KRAS vaccine in colon/pancreatic cancer. https://www.mskcc.org/news/vaccine-targeting-kras-in-pancreatic-and-colorectal-cancer-shows-promise

User Image Woooehoo Posted - 3 months ago

$ELTX https://finance.yahoo.com/news/elicio-therapeutics-announces-closing-private-200500908.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJ4dY-Jw7K9Xdh6_x5aa9nbSiYZh7UxGAq7Cj14fAdmA2F8KaP9dEOxi_Ww75q87ByHBUNHR2Hc3O1vtYX7Nw5V_p5syRk65zwV1qlL6xS03jV9ZaGvQ_S7AjtCELyobFCO_aCNvpXxarW50nrPCI6ajVr5z6xE0ye711UroxUFp

User Image Stock_Titan Posted - 3 months ago

$ELTX Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates https://www.stocktitan.net/news/ELTX/elicio-therapeutics-reports-second-quarter-2024-financial-results-7kftutxfheap.html

User Image HaltTradeAlert Posted - 3 months ago

$ELTX Halt Time: 09:30:18 Issue Symbol: ELTX Reason Code: LUDP Last Price: $5.06 Volume: 7.1 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

User Image Woooehoo Posted - 07/23/24

$ELTX what is the move...

User Image gooseandbear12 Posted - 4 months ago

$ELTX I’m out - thanks anyway - onto something better

User Image gooseandbear12 Posted - 4 months ago

$ELTX

User Image KCclean Posted - 4 months ago

$ELTX gap fill?

User Image gooseandbear12 Posted - 4 months ago

$ELTX

User Image gooseandbear12 Posted - 4 months ago

$ELTX ask is at 4 .. no doubt this pushes over 4 in AH

User Image gooseandbear12 Posted - 4 months ago

$ELTX $4 in AH

User Image gooseandbear12 Posted - 4 months ago

$ELTX this aged well 🤣🤣🤣🤡🤡

User Image Woooehoo Posted - 4 months ago

$ELTX going to 2 before settling

User Image gooseandbear12 Posted - 4 months ago

$ELTX

User Image abdsamad Posted - 4 months ago

$ELTX why inside holding at $5+ ... Extremely bullish

User Image Woooehoo Posted - 4 months ago

$ELTX we have a bottom…?

User Image NVDAMillionaire Posted - 06/30/24

$ELTX Elicio Therapeutics: Pioneering Lymph Node-Targeted Immunotherapies for Aggressive Cancers http://beyondspx.com/2024/06/30/elicio-therapeutics-pioneering-lymph-node-targeted-immunotherapies-for-aggressive-cancers/

User Image AnalRetort Posted - 06/29/24

@AG1011 @nhruch @Scooter0732 if anything goes down Monday it should be elicico $eltx Dr. Kasi is on their payroll not the agenus payroll.

User Image AnalRetort Posted - 06/29/24

@manny11419 one has nothing to do with the other, Kasi is an ist and not officially affiliated with agenus and if he did something improper it's on him. He did not develop bot or bal and has done no science on the agenus payroll in fact zero disclosure of any payment of any kind from agenus. Kasi is paid by elicio a key competitor in the space and has disclosed such. If anything $ELTX should crash not agen.

User Image justiceforb_85 Posted - 06/29/24

$ELTX remain positive about the preliminary data demonstrating that progression-free survival has not been reached for higher dose vaccine group. We'll see how this enfolds...

User Image Moneywheel Posted - 06/28/24

$ELTX daytrade: EP 3,57$ 400 shrs. GFTO

Analyst Ratings
HC Wainwright & Co. Buy Aug 23, 24
HC Wainwright & Co. Buy Jun 6, 24
HC Wainwright & Co. Buy May 22, 24
HC Wainwright & Co. Buy May 1, 24
Oppenheimer Perform Apr 1, 24
HC Wainwright & Co. Buy Jan 17, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chudnovsky Yekaterina Director Director Dec 22 Buy 5.81 1,213,000 7,047,530 1,915,639 12/26/23
Venkatesan Jay See Remarks See Remarks May 20 Buy 1.24 82,200 101,928 1,721,457 05/25/22
Nissenson Allen Director Director May 19 Buy 1.17 9,383 10,978 9,383 05/23/22
Venkatesan Jay See Remarks See Remarks Dec 16 Buy 2.55 41,625 106,144 1,358,486 12/20/21